Bio-Path Holdings is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Co.'s primary drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2, initially started the efficacy portion of a clinical trial for untreated acute myeloid leukemia patients in combination with low-dose cytarabine. Co.'s second drug candidate, Liposomal Bcl-2, targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The BPTH stock yearly return is shown above.
The yearly return on the BPTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BPTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|